PILLS Act
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
The PILLS Act establishes two federal tax credits to incentivize domestic production of generic drugs and biosimilars. The first credit provides a 30–35 percent tax credit on the value added by manufacturers producing generic drugs and biosimilars in the United States, with an additional bonus for domestic content in materials. The second credit provides a 25 percent investment tax credit for capital expenditures at facilities dedicated to generic drug and biosimilar production. Both credits phase out after 2029 and exclude manufacturers that are foreign entities of concern or subject to unresolved FDA warning letters.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.